Michael A. Caligiuri

Last updated
Michael A. Caligiuri
Born (1956-01-08) January 8, 1956 (age 67)
Buffalo, New York
CitizenshipAmerican
Alma mater
Known forhuman natural killer cells
SpouseAna Maria de Jesús Caligiuri [1]
Children3
AwardsThe J.E. Wallace Sterling Lifetime Achievement Award in Medicine Stanford University School of Medicine [2]
Scientific career
Fields oncology immunology
Institutions

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. [3] He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. [4] He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. [5] [6] [7] [8] [9] [10] He was elected to the United States National Academy of Medicine in 2018. [11]

Contents

Early life and education

Caligiuri was born in Buffalo, N.Y. on January 8, 1956, to Michael Angelo Caligiuri and Louise Rita (Mutignani) Caligiuri. He is the second of their 10 children. He is of Italian descent. His four grandparents, each uneducated and impoverished, emigrated separately from southern Italy to Buffalo, NY between 1913 and 1920. Quirino and Nineta (DeMarzio) Mutignani emigrated from Spoltore, Italy. Quirino then worked as a steam pressor at the M. Wile and Company Factory Building. Rosario Caligiuri emigrated from Soveria Mannelli, Italy and performed urban labor and migrant work. Sebastiana (Giampaolo) Caligiuri emigrated from Accadia, Italy and was a migrant worker, as were their five children. Caligiuri's father was a salesman and his mother was a homemaker. He was raised in a strict Catholic household. He attended Blessed Sacrament Elementary School and St. Joseph's Collegiate Institute for high school. He majored in humanities and health science at the State University of New York at Buffalo while living at home. He graduated summa cum laude and Phi Beta Kappa. Caligiuri, along with his siblings worked in a bingo hall every weekend at St. Colomba's Catholic Church in the inner city of Buffalo selling refreshments from the age of 8 until 21 to help with family and educational expenses. Caligiuri also worked as a janitor, house painter, and construction worker throughout high school, and as a waiter and wine steward to pay for college. Although there were no medical personnel in the family, Caligiuri always wanted to become a medical doctor.

In 1974, while a high school summer research student at Roswell Park Memorial Institute in Buffalo, N.Y. (now Roswell Park Comprehensive Cancer Center), Caligiuri won the Sydney Farber Award for Outstanding Research. The award was presented by Eugene Farber, MD, the brother of the late Sydney Farber and the Chairman of the Department of Dermatology at Stanford University School of Medicine. [12] Dr. Farber invited Caligiuri to spend the following summer with him at Stanford University School of Medicine, marking the first time Caligiuri left Buffalo. Before completing college, Caligiuri also spent time studying humanities in Pisa, Italy. These two experiences proved to be invaluable in shaping Caligiuri's career aspirations and curiosity as he pursued a course of medicine and science. [13] [14]

Caligiuri applied to and was accepted at Stanford University School of Medicine in 1978 to pursue a degree in Medicine but without a means to pay for the education. He entered the 5-year medical scholars program (now called The Discovery Curriculum) [15] that allowed him to work in a laboratory for 3 years of his pre-clinical training providing free tuition and living expenses for the 3 years, as well as offering free tuition for year 5, the second clinical clerkship training year. Caligiuri worked as a basic science researcher in the laboratory of Eugene Debs Robin, M.D. a pulmonologist and respiratory physiologist who was chief of the division of pulmonary medicine, acting chairman of the department of physiology, and in charge of the year-long physiology course in the school of medicine. [16] Caligiuri studied the diving reflexes of seals, porpoises, and turtles for three years while completing his pre-clinical coursework, and spent the summers of 1978 and 1979 with Dr. Robin's lab at the Scripps Oceanographic Institute in La Jolla, CA. His first publications resulted from this experience,. [17] [18] Caligiuri delivered the two lectures on the autonomic nervous system of the heart to the first year Stanford medical students from 1979 through 1982, and obtained his master's degree in physiology from the Stanford University School of Medicine in 1982. In 1983, his final year of medical school, Caligiuri was involved in successfully reversing the rejection of a transplanted kidney in a patient receiving what was then an experimental drug (cyclosporine). That single event inspired him to pursue immunology and clinical transplantation as a career. [14] Following graduation from medical school in 1983 he next trained at Harvard in internal medicine at the Brigham and Women's Hospital (1983-1986) and in oncology, immunology and bone marrow transplantation at the Dana Farber Cancer Institute (1986-1989). Caligiuri published his first immunology paper from work he performed in the laboratory of his mentor, Jerome Ritz, MD [19] on human natural killer cells or NK cells while working as a senior resident in internal medicine in 1985. [20]

Personal life

In 1983 Caligiuri met Ana Maria de Jesus Pou, a nutritionist at the Brigham and Women's Hospital originally from Ponce, Puerto Rico. They married in 1985 and have 3 children and 1 grandchild. [1]

Career

Caligiuri joined the faculty at Harvard Medical School following completion of his fellowship in the summer of 1989, but financial pressures quickly led him to the realization that he needed to move. In the fall of 1989 he was recruited to Roswell Park Memorial Institute in Buffalo, N.Y. (now Roswell Park Comprehensive Cancer Center) as an assistant professor by Clara D. Bloomfield, MD who subsequently became his life-long mentor. [21] [22] He had success in the clinic and the laboratory and rose to a full professor in seven years. In 1997 Caligiuri moved with Bloomfield and her husband, Albert de la Chapelle, MD, PhD to Ohio State University as the associate director for clinical research in the OSU comprehensive cancer center (OSUCCC) and co-director of the division of hematology-oncology. He was appointed as the director of the division of hematology-oncology from 2003 to 2007 and in 2005 succeeded Bloomfield as director of the OSUCCC until 2017. In 2007, Caligiuri was also appointed CEO of OSU's James Cancer Hospital until 2017. During his tenure Caligiuri recruited over 300 cancer physicians and researchers; the OSUCCC received a perfect score on peer-review from the National Cancer Institute (the first ever for a matrix CCC in the USA); and he oversaw the construction of a new James Cancer Hospital, the third largest cancer hospital in the USA. [5] [6] [7] [8] [9] [10] Caligiuri stepped down as director of the OSUCCC and CEO of the James Cancer Hospital in December 2017. [23] In February 2018 Caligiuri was appointed as the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. [3]

Research

Caligiuri is a physician – scientist whose basic laboratory work for 35 years has focused on understanding the role of human natural killer cells or NK cells in defense against cancer and infection. He trained in human immunology at the Dana Farber Cancer Institute in the laboratory of Jerome Ritz, [19] from 1987 to 1989, focused exclusively on NK cells. The Caligiuri laboratory has published over 400 original peer-reviewed publications on NK cells and/or cancer [24] and has numerous patents relating to immunology. Pivotal discoveries from the Caligiuri laboratory contributed to bringing chimeric antigen receptor (CAR) NK cells from the laboratory into the clinic for cancer therapy. These discoveries include proprietary retroviral transduction of human NK cells, the elucidation of the site, stages, cytokines and molecular mechanisms involved in the differentiation of human NK cells from CD34(+) hematopoietic stem cells, and the discovery of IL-15 as the key cytokine for human NK cell development, survival, growth, and activation. These three discoveries alone have been critical for the genesis of CAR NK cells from peripheral blood, umbilical cord blood and induced pluripotent stem cells (iPSCs). All of this work was accomplished with his predoctoral and postdoctoral students as well as his former postdoctoral student and now long-term collaborator, Jianhua Yu, PhD. [25] Caligiuri's research has been continually funding by the National Institute of Health for 32 years, including a MERIT award and an Outstanding Investigator Award. In 2018 Caligiuri received the J.E. Wallace Sterling Lifetime Achievement Award in Medicine from Stanford University, [26] was elected as a fellow in the AACR Academy [27] and was elected to the United States National Academy of Medicine [28] for his work in immunology.

Translational and Entrepreneurial Efforts

Dr. Caligiuri has designed and conducted clinical studies modulating NK cells for over 1,000 patients with cancer as well as AIDS. He co-founded CytoImmune Therapeutics, a clinical stage biopharmaceutical company in 2017 to bring NK cell therapies to patients. [29] CytoImmune Therapeutics is the first cell therapy company established in Puerto Rico. [30] Caligiuri also co-founded The Oncology Research Information Exchange Network [31] in 2014, CancerBridge [32] in 2014, and the Ohio State University Drug Development Institute [33] in 2013.

Education

Over 120 students have trained in the Caligiuri laboratories at Roswell Park Cancer Institute, The Ohio State University, and City of Hope. His students have received over 200 local, state, national or international awards for their research. [34]

Other

Upon being named CEO of The James Cancer Hospital in 2007, Caligiuri had the idea to start a grassroots bike event one weekend a year in Columbus, OH to raise money for cancer research at the OSUCCC. Together with Cindy Hilsheimer [35] and Daniel Rosenthal, [36] Caligiuri co-founded Pelotonia [37] in 2008, with the first ride occurring in 2009. In its first 13 years, Pelotonia has raised over $236 million for cancer research. 100% of all participant-raised funds go toward innovative cancer research.

Honors and awards

Related Research Articles

<span class="mw-page-title-main">Emil Frei</span> American physician and oncologist

Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.

<span class="mw-page-title-main">John E. Niederhuber</span>

John E. Niederhuber, MD was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.

<span class="mw-page-title-main">Larry Kwak</span> American cancer researcher

Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.

Leonard I. Zon, M.D., is the Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, and Director of the Stem Cell Program, Children’s Hospital Boston.

Clara Derber Bloomfield, was an American physician and cancer researcher. Her work focused on the genetic changes that are present in certain types of blood cancers, and how those can be utilized to improve treatment for the affected patients.

Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.

<span class="mw-page-title-main">Harvey Cantor</span> American immunologist

Harvey Cantor is an American immunologist known for his studies of the development and immunological function of T lymphocytes. Cantor is currently the Baruj Benacerraf Professor of Immunology and Microbiology at the Harvard Medical School.

<span class="mw-page-title-main">Douglas R. Lowy</span>

Douglas R. Lowy is the current Principal Deputy Director of the U.S. National Cancer Institute (NCI) and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy served as Acting Director of NCI between April 2015 and October 2017 following the resignation of Harold E. Varmus, M.D., and again between April and November 2019, while Director Norman Sharpless served as the Acting Commissioner of the U.S. Food and Drug Administration. He resumed the role of Acting Director on May 1, 2022, when Sharpless stepped down until October 3, 2022 when Monica Bertagnolli was appointed Director. He resumed the role again in November 2023 after Bertagnolli resigned to serve as director of the National Institutes of Health.

Owen Witte is an American physician-scientist at the University of California, Los Angeles. He is a distinguished professor of microbiology, immunology and molecular genetics in the David Geffen School of Medicine at UCLA, founding director of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the UC Regents’ David Saxon Presidential Chair in developmental immunology (1989–present). Witte is also a Howard Hughes Medical Institute investigator (1986–present) and a member of the President's Cancer Panel. He also served on the Life Sciences jury for the Infosys Prize in 2013.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana–Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.

<span class="mw-page-title-main">Carl H. June</span> American immunologist and oncologist

Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.

<span class="mw-page-title-main">Daniel Von Hoff</span>

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

Robert Maki is an American medical oncologist, Professor of Medicine at the Hospital of the University of Pennsylvania, He is a specialist in the management of and translational research regarding sarcoma, the group of connective tissue malignancies that include leiomyosarcoma, gastrointestinal stromal tumor (GIST), liposarcoma, angiosarcoma, Ewing sarcoma, desmoid tumor and many others.

Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.

Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

Adekunle O. Odunsi is an American gynecologic oncologist. In 2020, Odunsi was named the director of the University of Chicago Comprehensive Cancer Center.

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

References

  1. 1 2 "Leading by Example: Dr. Michael and Ani Caligiuri".
  2. ↑ "Alumni Awards 2018".
  3. 1 2 "City of Hope Names Michael A. Caligiuri as President of City of Hope National Medical Center" (Press release). 28 November 2017.
  4. 1 2 "Michael A. Caligiuri, MD, Named American Association for Cancer Research President-Elect 2016–2017". aacr.org. Retrieved 2016-11-18.
  5. 1 2 "Reaching a Perfect Rating".
  6. 1 2 "From Buffalo to Columbus".
  7. 1 2 "Turning Around the OSUCCC – James".
  8. 1 2 "A Day in the Life".
  9. 1 2 "The Three Pillars of Leadership".
  10. 1 2 "What's Next – Improving Upon Perfection".
  11. ↑ "National Academy of Medicine Elects 85 New Members". 15 October 2018.
  12. ↑ Harris, David R.; Walton, Robert (July 2001). "Eugene M. Farber, MD (1917-2000)". Archives of Dermatology. 137 (7): 938–939.
  13. ↑ "From Buffalo to Columbus".
  14. 1 2 "Sterling Award".
  15. ↑ "Discovery Curriculum".
  16. ↑ "Memorial Resolution: Eugene Debs Robin". 4 May 2005.
  17. ↑ Calioiuri, Michael A.; Robin, Eugene D. (1985). "Prolonged diving and recovery in the freshwater turtle, Pseudemys scripta—IV. Effects of profound acidosis on O2 consumption in turtle vs rat (Mammalian) brain and heart slices". Comparative Biochemistry and Physiology Part A: Physiology. 81 (3): 603–605. doi:10.1016/0300-9629(85)91034-5. PMID   2863049.
  18. ↑ Hance, A. J.; Robin, E. D.; Halter, J. B.; Lewiston, N.; Robin, D. A.; Cornell, L.; Caligiuri, M.; Theodore, J. (1982). "Hormonal changes and enforced diving in the harbor seal Phoca vitulina. II. Plasma catecholamines". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 242 (5): R528–R532. doi:10.1152/ajpregu.1982.242.5.r528. PMID   7081478.
  19. 1 2 "Jerome Ritz, MD - Dana–Farber Cancer Institute | Boston, MA".
  20. ↑ Caligiuri, M.; Murray, C.; Buchwald, D.; Levine, H.; Cheney, P.; Peterson, D.; Komaroff, A. L.; Ritz, J. (1987). "Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome". Journal of Immunology. 139 (10): 3306–3313. doi: 10.4049/jimmunol.139.10.3306 . PMID   2824604. S2CID   44286946.
  21. ↑ Caligiuri, Michael A. (2020). "You Must Remember Meeting Clara: Remembering Clara Derber Bloomfield (1942–2020)". Cancer Research. 80 (9): 1787–1789. doi: 10.1158/0008-5472.CAN-20-0959 . S2CID   218811872.
  22. ↑ "The Legacy of Dr. Clara Bloomfield (1942–2020) | OSUCCC – James".
  23. ↑ "Caligiuri: It was time for me to hit the refresh button on my career". 28 November 2017.
  24. ↑ "Caligiuri ma - Search Results - PubMed".
  25. ↑ https://www.google.com/search?q=jianhua+yu+city+of+hope.{{cite web}}: Missing or empty |title= (help)
  26. ↑ "Alumni Awards 2018".
  27. ↑ "Michael A. Caligiuri, MD".
  28. ↑ "Michael Caligiuri, M.D., Elected to National Academy of Medicine | City of Hope".
  29. ↑ "Home". cytoimmune.com.
  30. ↑ "CytoImmune Therapeutics, Inc. Opens the Company's Clinical Cell Manufacturing Facility in Toa Baja". 24 March 2022.
  31. ↑ "Home". ORIENcancer.org.
  32. ↑ "CancerBridge - Home".
  33. ↑ "Drug Development Institute | OSUCCC – James".
  34. ↑ "Caligiuri ma - Search Results - PubMed".
  35. ↑ "Cindy Hilsheimer | the Ohio State University".
  36. ↑ https://www.linkedin.com/in/daniel-rosenthal-0524b37/ [ self-published source ]
  37. ↑ "Home". pelotonia.org.
  38. ↑ (PDF) https://aimbe.org/press/caligiuri-COF-7011.pdf.{{cite web}}: Missing or empty |title= (help)
  39. ↑ "National Academy of Medicine Elects 85 New Members". National Academy of Medicine. 15 October 2018. Retrieved 2 May 2019.
  40. ↑ "2018 Archives".
  41. ↑ "Alumni Awards 2018".
  42. ↑ https://www.sni-online.org/.{{cite web}}: Missing or empty |title= (help)
  43. ↑ National Cancer Policy Forum. National Academies Press (US). 23 December 2014.
  44. ↑ "2016 NCI Outstanding Investigator Award Recipients - NCI". 14 October 2015.
  45. ↑ "Ohio State Cancer Leader Dr. Caligiuri Elected to AACR Board of Directors".
  46. ↑ "ASH Executive Committee Election Results Announced". The Hematologist. 7 (6). 2010. doi:10.1182/hem.V7.6.6403.
  47. ↑ "Caligiuri earns award".
  48. ↑ "Association of American Cancer Institutes Elects Caligiuri". Cancer Biology & Therapy. 6 (10): 1516. 2007. doi: 10.4161/cbt.6.10.5468 . S2CID   219321298.
  49. ↑ "Previous AACR Meetings: 2009".
  50. ↑ (PDF) https://deainfo.nci.nih.gov/advisory/bsa/archive/bsa0608/23jun08mins.pdf.{{cite web}}: Missing or empty |title= (help)
  51. ↑ "John Wayne Clinical Research Lecturers".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.